Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Subscribe To Our Newsletter & Stay Updated